The power of an immunotherapy can be added to COTELLIC + ZELBORAF9
Learn more about this combination and appropriate patients >
The power of an immunotherapy can be added to COTELLIC + ZELBORAF9
Learn more about this combination and appropriate patients >
At Genentech Access Solutions, we are dedicated to ensuring our medications are accessible for the patients who need them. We can help your patients and practice address each patient’s coverage scenario.
Is your patient insured?
Does the patient's insurance cover his or her Genentech medicine?
Has your patient already been referred to the Genentech Oncology Co-pay Assistance Program and is either ineligible or no longer receiving assistance?
Has your patient already been referred to an independent co-pay assistance foundation and is either ineligible or no longer receiving assistance?
Is the patient 18 years of age or older?
Your Patient Might Qualify for a Referral to the Genentech Oncology Co-pay Assistance Program
If eligible commercially insured patients need assistance with their out-of-pocket costs, COTELLIC and ZELBORAF Access Solutions can refer them to the Genentech Oncology Co-pay Assistance Program.*
*Eligibility criteria apply. Not valid for patients using federal or state government programs to pay for their medications and or administration of their Genentech medication. Patient must be taking the Genentech medication for an FDA-approved indication. See full Terms and Conditions at CopayAssistanceNow.com.
Your Patient Might Qualify for a Referral to an Independent Co-pay Assistance Foundation
For eligible patients with commercial or public health insurance, COTELLIC and ZELBORAF Access Solutions offers referrals to independent co-pay assistance foundations.*
*Advise your patient that these organizations are independent of Genentech and may require the patient to provide personal or financial information directly to the organization to enroll in their respective programs. Genentech cannot share any information the patient has provided to us.
Independent co-pay assistance foundations have their own rules for eligibility. We have no involvement or influence in independent foundation decision-making or eligibility criteria and do not know if a foundation will be able to help your patient. We can only refer your patient to a foundation that supports their disease state. This information is provided as a resource for you. We do not endorse or show preference for any particular foundation. The foundations in this list may not be the only ones that might be able to help your patient.
Your Patient Might Qualify for a Referral to the Genentech Patient Foundation
The Genentech Patient Foundation provides free Genentech medicine to people who don't have insurance coverage or who have financial concerns and meet eligibility criteria.*
*To be eligible for free Genentech medicine from the Genentech Patient Foundation, insured patients who have coverage for their medicine should try to pursue other forms of financial assistance, if available, and meet certain income requirements. Uninsured patients and insured patients without coverage for their medicine must meet a different set of income requirements.
GATCF provides free medicine to eligible patients who are uninsured, rendered uninsured by payer denial, or underinsured. To qualify, patients must meet specific criteria. For more information, call (888) 249-4918 or visit Genentech-Access.com/Oncology*.
*To be eligible for free medicine from GATCF, insured patients must have exhausted all other forms of patient assistance (including Genentech brand-specific co-pay cards and support from independent co-pay assistance foundations) and meet additional criteria.
Commercially insured patients may be eligible for the Genentech Oncology Co-pay Card† if they:
†In order to be eligible for the Genentech Oncology Co-pay Card, the patient must confirm that they meet the eligibility criteria and agree to the rules set forth in the terms and conditions for the program. Please visit CopayAssistanceNow.com for the full list of terms and conditions.
Genentech Access Solutions offers referrals to independent co-pay assistance foundations‡ for eligible patients who are commercially or publicly insured, including those covered by Medicare and Medicaid.
Key points to remember about independent co-pay assistance foundation referrals:
To view a list of potential independent co-pay assistance foundations, visit Genentech-Access.com/Oncology.
‡Genentech does not influence or control the operations or eligibility criteria of any independent co-pay assistance foundation and cannot guarantee co-pay assistance after a referral from Genentech Access Solutions. The foundations to which we refer patients are not exhaustive or indicative of Genentech's endorsement or financial support. There may be other foundations to support the patient's disease state.
Explore and download resources for your patients and your practice
Get information about
financial assistance and more
COTELLIC Prescribing Information. Genentech, Inc. 2016.
COTELLIC Prescribing Information. Genentech, Inc. 2016.
Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371:1867-1876.
Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371:1867-1876.
Data on file. Genentech, Inc.
Data on file. Genentech, Inc.
ZELBORAF Prescribing Information. Genentech, Inc. 2017.
ZELBORAF Prescribing Information. Genentech, Inc. 2017.
Department of Health and Human Services (DHHS). New Drug Application (NDA) approval 202429 [letter]. Food and Drug Administration. 2011.
Department of Health and Human Services (DHHS). New Drug Application (NDA) approval 202429 [letter]. Food and Drug Administration. 2011.
Bollag G, Tsai J, Zhang J, et al. Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov. 2012;11:873-886.
Bollag G, Tsai J, Zhang J, et al. Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov. 2012;11:873-886.
Santarpia L, Lippman SL, El-Naggar AK. Targeting the mitogen-activated protein kinase RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16:103-119.
Santarpia L, Lippman SL, El-Naggar AK. Targeting the mitogen-activated protein kinase RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16:103-119.
Chen G, Davies MA. Targeted therapy resistance mechanisms and therapeutic implications in melanoma. Hematol Oncol Clin North Am. 2014;28:523-536.
Chen G, Davies MA. Targeted therapy resistance mechanisms and therapeutic implications in melanoma. Hematol Oncol Clin North Am. 2014;28:523-536.
TECENTRIQ Prescribing Information. Genentech, Inc. 2020.
TECENTRIQ Prescribing Information. Genentech, Inc. 2020.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.